MX2010001608A - Suministro mediado por aav auto-complementario de moléculas de arn interferente para tratar o evitar trastornos oculares. - Google Patents

Suministro mediado por aav auto-complementario de moléculas de arn interferente para tratar o evitar trastornos oculares.

Info

Publication number
MX2010001608A
MX2010001608A MX2010001608A MX2010001608A MX2010001608A MX 2010001608 A MX2010001608 A MX 2010001608A MX 2010001608 A MX2010001608 A MX 2010001608A MX 2010001608 A MX2010001608 A MX 2010001608A MX 2010001608 A MX2010001608 A MX 2010001608A
Authority
MX
Mexico
Prior art keywords
interfering rna
treat
rna molecules
ocular disorders
mediated delivery
Prior art date
Application number
MX2010001608A
Other languages
English (en)
Spanish (es)
Inventor
Allan R Shepard
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2010001608A publication Critical patent/MX2010001608A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2010001608A 2007-10-01 2008-10-01 Suministro mediado por aav auto-complementario de moléculas de arn interferente para tratar o evitar trastornos oculares. MX2010001608A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97655207P 2007-10-01 2007-10-01
PCT/US2008/078380 WO2009046059A1 (en) 2007-10-01 2008-10-01 Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders

Publications (1)

Publication Number Publication Date
MX2010001608A true MX2010001608A (es) 2010-03-15

Family

ID=40042637

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001608A MX2010001608A (es) 2007-10-01 2008-10-01 Suministro mediado por aav auto-complementario de moléculas de arn interferente para tratar o evitar trastornos oculares.

Country Status (12)

Country Link
US (1) US20090087413A1 (https=)
EP (1) EP2192926A1 (https=)
JP (1) JP2010540564A (https=)
KR (1) KR20100061792A (https=)
CN (1) CN101815536A (https=)
AU (1) AU2008308784B2 (https=)
BR (1) BRPI0817937A2 (https=)
CA (1) CA2694091A1 (https=)
MX (1) MX2010001608A (https=)
RU (1) RU2010117178A (https=)
WO (1) WO2009046059A1 (https=)
ZA (1) ZA201000423B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2287323A1 (en) * 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
SG10201800541SA (en) 2010-04-23 2018-03-28 Univ Florida Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
CN103505743A (zh) 2012-06-21 2014-01-15 北京命码生科科技有限公司 含功能性microRNA/siRNA的细胞微粒子及其应用
SG11201702055PA (en) * 2014-09-16 2017-04-27 Genzyme Corp Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
PL4012035T3 (pl) * 2014-09-16 2025-03-24 Genzyme Corporation Wektory wirusowe związane z adenowirusami do leczenia jaskry miocylinowej (myoc)
EP4012035B1 (en) * 2014-09-16 2024-11-06 Genzyme Corporation Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
GB201809588D0 (en) * 2018-06-12 2018-07-25 Univ Bristol Materials and methods for modulating intraocular and intracranial pressure
KR20220076510A (ko) 2019-10-08 2022-06-08 트러스티스 오브 보스톤 칼리지 다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
WO2021245224A1 (en) * 2020-06-05 2021-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating ocular diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318923T1 (de) * 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050048529A1 (en) * 2002-02-20 2005-03-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) * 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2005019422A2 (en) * 2003-08-13 2005-03-03 The Board Of Trustees Of The University Of Illinois Silencing of tgf-beta receptor type ii expression by sirna
WO2006042252A2 (en) * 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
TW200639252A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
WO2006099353A1 (en) * 2005-03-11 2006-09-21 Alcon, Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
AR057252A1 (es) * 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
TW200731980A (en) * 2005-12-29 2007-09-01 Alcon Mfg Ltd RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
TW201336514A (zh) * 2006-04-13 2013-09-16 Alcon Res Ltd ＲＮＡ干擾（ＲＮＡｉ）所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用（二）
WO2007127428A2 (en) * 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
US7732421B2 (en) * 2006-05-19 2010-06-08 Alcon Research, Ltd. RNAI-mediated inhibition of tumor necrosis factor α-related conditions
KR20090042297A (ko) * 2006-08-24 2009-04-29 알콘 리서치, 리미티드 ＩＯＰ―관련 증상을 치료하기 위한 그렘린의 ＲＮＡｉ 매개 억제
US7872119B2 (en) * 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
TW200932274A (en) * 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof

Also Published As

Publication number Publication date
KR20100061792A (ko) 2010-06-09
CN101815536A (zh) 2010-08-25
CA2694091A1 (en) 2009-04-09
US20090087413A1 (en) 2009-04-02
AU2008308784A1 (en) 2009-04-09
ZA201000423B (en) 2011-03-30
BRPI0817937A2 (pt) 2015-04-07
RU2010117178A (ru) 2011-11-10
EP2192926A1 (en) 2010-06-09
AU2008308784B2 (en) 2013-07-18
JP2010540564A (ja) 2010-12-24
WO2009046059A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
MX2010001608A (es) Suministro mediado por aav auto-complementario de moléculas de arn interferente para tratar o evitar trastornos oculares.
WO2022032154A3 (en) Compositions for the delivery of payload molecules to airway epithelium
EP4603144A3 (en) Cns gene delivery using peripherical administration of aav vectors
MX2020011746A (es) Terapias genicas para los trastornos lisosomales.
WO2008156702A3 (en) Bacteria mediated gene silencing
WO2019070891A8 (en) Gene therapies for lysosomal disorders
EA201692206A1 (ru) Векторы на основе aav для генной терапии в сетчатке и cns
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
MX2022012524A (es) Adeno-asociado para administracion terapeutica al sistema nervioso central.
WO2010129746A3 (en) Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2009134681A3 (en) Adeno associated viral vectors for targeted transduction of retinal pigment epithetial cells
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2010135695A3 (en) TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
WO2011085066A3 (en) Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
WO2010129861A3 (en) Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
MX389903B (es) Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal.
WO2011082281A3 (en) Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
MX388146B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
WO2008132723A3 (en) Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
MX2013000321A (es) Suministro al sistema nervioso central de agentes terapeuticos.
BR112015005227A2 (pt) inibidores de glicosilceramida sintase
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
WO2011017516A3 (en) Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal